Time has come for immunotherapy in PTCL.
In this issue of Blood, Horwitz et al present encouraging results of a phase 2 study assessing the efficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) in relapsed/refractory peripheral T-cell lymphoma (PTCL).
UNIVERSITY LYON 1.
Emmanuel
E
Bachy
UNIVERSITY LYON 1.
Bertrand
http://orcid.org/0000-0003-2740-717X
B
Coiffier
D000079963:Brentuximab Vedotin; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D018796:Immunoconjugates; D000079963:Brentuximab Vedotin